
Opinion|Videos|September 12, 2024
JAK Inhibitor Selectivity and Dose-Related Toxicity
Panelists discuss how the varying selectivity of JAK inhibitors—such as tofacitinib's broad inhibition of JAK1/JAK2/JAK3, baricitinib's inhibition of JAK1/JAK2, and upadacitinib's focus on JAK1—affects dose-related toxicity and overall treatment safety.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Mechanism of action also differs in the Janus kinase (JAK) inhibitor class. Tofacitinib inhibits JAK1/JAK2/JAK3, baricitinib inhibits JAK1/JAK2, and upadacitinib inhibits JAK1. Can you describe how more specific selectivity of JAK inhibition influences dose-related toxicity?
Advertisement
Related to this article

A FIBRONEER-ILD subgroup analysis presented at ACR 2026 found no heterogeneity in nerandomilast's effect on FVC decline or clinical events.

Secukinumab 150 mg doubled week-52 sustained remission vs placebo in REPLENISH, making it the first anti-IL-17 biologic approved for PMR.

Afimetoran achieved SRI-4 response rates of 64.1% to 67.8% vs 34.4% with placebo in a phase 2 SLE trial.

The 200-mg dose improved ACR20 response vs placebo at week 16 in biologic-naïve patients, while the 400-mg dose added no benefit.

An international IgG4ward! Foundation panel issued 28 treatment statements for IgG4-related diseases, with consensus reached on 22.

In 33 patients with myositis-associated ILD from FIBRONEER-ILD, nerandomilast numerically slowed FVC decline and lowered progression risk.

RESET-RA 24-month data show sustained clinical responses with vagus nerve stimulation in patients with treatment-experienced RA.
Advertisement
Advertisement

